The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2022 | ARI-0001 CAR-T therapy for R/R CLL and Richter’s syndrome
Valentín Ortiz-Maldonado, MD, Hospital Clínic de Barcelona, Barcelona, Spain, comments on the use of chimeric antigen receptor T-cells (CAR-T) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Patients who fail on ibrutinib or venetoclax and also have a high-risk genetic profile such as TP53 mutations or complex karyotype have worse outcomes with tailored CAR T-cell therapy than other malignancies treated with standard CAR-T. Toxicity results of experimental ARI-0001 (varnimcabtagene autoleucel) in 8 R/R patients with CLL/Richter’s transformation showed CRS in 87%, severe in 12% of cases, and 37% required tocilizumab, but no cases of immune effector cell-associated neurotoxicity syndrome (ICANS) were observed. Efficacy results show 100% measurable residual disease (MRD)-negative complete response (CR) for the CLL component and 60% non-relapse complete metabolic responders for Richter transformation, opening the perspectives for CAR-T treatment for these groups of patients. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.
Disclosures
Research grants: Fundación Española de Hematología y Hemoterapia
Travel grants: Kite, Celgene, Novartis, Roche, Takeda & Janssen
Consultant or advisory fees: Kite, Celgene-BMS, Novartis & Janssen
Honoraria: Kite
Employment: Hospital Clínic, Barcelona
